Home › Compare › ENMFF vs ABBV
ENMFF yields 200000000.00% · ABBV yields 3.06%● Live data
📍 ENMFF pulled ahead of the other in Year 1
Combined, ENMFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENMFF + ABBV for your $10,000?
Energem Resources Inc., through its subsidiaries, engages in the mid and up-stream oil and related sectors in Africa. It operates in four divisions: Up-Stream Oil, Logistics and Industrial, Biofuels, and Mid-Stream Oil. The Up-Stream Oil division engages in the exploration and development of an oil and gas field in Chad. The Logistics and Industrial division engages in the manufacture, procurement, supply, and logistics management of and for products primarily to the mining industry in sub-Saharan Africa. It also owns and manages a bitumen emulsions manufacturing factory in Harare, Zimbabwe. The Biofuels division produces potable alcohol and industrial ethanol for use in beverage, medical, and industrial applications, as well as develops a bio-diesel project in Mozambique. The Mid-Stream division sells refined fuel products. Energem Resources Inc. was formerly known as DiamondWorks Ltd and changed its name to Energem Resources Inc. in June 2004. The company was incorporated in 1966 and is headquartered in Johannesburg, South Africa. Energem Resources Inc. is in liquidation.
Full ENMFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.